echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Aosaikang's subsidiary Polymyxin E Methanesulfonate Sodium for Injection Obtained Drug Registration Approval

    Aosaikang's subsidiary Polymyxin E Methanesulfonate Sodium for Injection Obtained Drug Registration Approval

    • Last Update: 2021-11-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On October 21, Osaikang issued an announcement stating that its subsidiary, Jiangsu Osaikang’s Sodium Polymyxin E Methanesulfonate for Injection, had recently been approved for drug registration by the National Medical Products Administration


    Polymyxin E sodium methanesulfonate for injection is a polypeptide antibiotic.


    The emergence of gram-negative bacteria resistance, especially carbapenem-resistant bacteria, multi-drug resistant bacteria, pan-drug resistant bacteria, and even new types of "super bacteria" has made clinically available effective therapeutic drugs less and less


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.